India's Wockhardt Launches Drug in US Market

Indian pharma major Wockhardt Wednesday announced the launch of its antibiotic tablets Cefprozil in the US after receiving approval from the US Food and Drug Administration (US FDA).

Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections.

"Several of our products have seen a dramatic increase in the market share in the US over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million," Wockhardt chairman Habil Khorakiwala said in a statement.

The Cefprozil tablets, developed in-house, are manufactured at Wockhardt's US FDA certified formulation plant at Waluj in Maharashtra.

The $650 million firm has a market capitalisation of over $1 billion and has major presence in the markets of the US, Britain, Ireland, Germany and France. It employs over 7,000 professionals both in India and abroad.

Source-IANS
LIN/M